GlassScriptPhysician profile
Joseph Troise
NPI 1285629345
$143,871.32
in general payments reported to CMS, 2019-2025
25 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,966 · 2020: $4,336 · 2021: $15K · 2022: $41K · 2023: $27K · 2024: $29K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $72K · Food and Beverage: $2,530 · Travel and Lodging: $1,641 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $72,340.59 |
| Food and Beverage | $2,530.21 |
| Travel and Lodging | $1,640.92 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $123,242.82 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $18,387.81 | 2019-2021 | |
| Abbvie INC. | $470.41 | 2019-2023 | Lo Loestrin Fe |
| Minerva Surgical, INC | $354.83 | 2021-2024 | |
| Astellas Pharma US INC | $346.35 | 2020-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $238.91 | 2019-2023 | |
| Amgen INC. | $155.90 | 2020-2024 | Evenity |
| Hologic Sales and Service, LLC | $126.72 | 2019-2022 | |
| Exeltis, USA INC. | $108.35 | 2022-2023 | Slynd |
| Baxter Healthcare | $70.79 | 2019 | |
| Biogen, INC. | $69.32 | 2024-2025 | Zurzuvae |
| Shire North American Group INC | $33.33 | 2019 | |
| Amag Pharmaceuticals, INC. | $32.03 | 2019 | |
| Si-Bone, INC. | $31.04 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $24.53 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.09 | 2022 | |
| Shield Therapeutics INC | $22.23 | 2023 | Accrufer |
| Mayne Pharma Commercial LLC | $21.34 | 2023 | |
| Myovant Sciences INC. | $20.70 | 2022 | |
| Sumitomo Pharma America, INC. | $17.25 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $15.91 | 2019 | |
| Abbott Laboratories | $15.88 | 2023 | Proclaim |
| Lilly USA, LLC | $15.29 | 2025 | Zepbound, Mounjaro |
| Avion Pharmaceuticals | $14.36 | 2021 | |
| Pfizer INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Troise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.